Kate Therapeutics and Capsida Biotherapeutics collaborate on gene therapies
The companies aim to bring gene therapies to patients sooner than traditional approaches
Read More
Tag: Muscular dystrophy
FDA rejects PTC’s DMD drug Translarna
PTC Therapeutics will need to carry out at least one further trial to demonstrate the effectiveness of its Duchenne Muscular Dystrophy therapy Translarna if it is to have a chance of bagging its approval in the US.
Read More
Charity slams government’s lack of response to access issues
Muscular Dystrophy UK is campaigning for faster approval and funding for therapies for children and adults with muscle-wasting treatments, and warns that the wait for a government response to the Accelerated Access Review “adds to delays to new drugs”.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
